Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 5/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | HPGDS | O60760 | 2/20 | 0.39 |
| ▸ | ELANE | P08246 | 2/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14330665 | 0.85 | ACSS2 (0.40) | MAOBACSS2KDM4EGAAMEN1 | |
| SCHEMBL14330657 | 0.83 | ALDH1A1 (0.42) | MAOBACSS2KDM4EGAASMN1; SMN2 | |
| SCHEMBL17583176 | 0.79 | POLB (0.46) | TP53POLBELANEGRIN2BGAA | |
| SCHEMBL28701482 | 0.75 | MAOB (0.57) | TP53MAOBPOLBHPGDSELANE | |
| SCHEMBL29365635 | 0.75 | MAOB (0.57) | TP53MAOBPOLBHPGDSELANE | |
| SCHEMBL14331598 | 0.74 | CES2 (0.38) | TP53DYRK1AHPGDSPDE10AMEN1 | |
| SCHEMBL21225586 | 0.74 | PDE10A (0.46) | TP53DYRK1AHPGDSPDE10AGAA | |
| SCHEMBL24701948 | 0.72 | ALDH1A1 (0.46) | KDM4EGAAHSD17B10MEN1KMT2A | |
| SCHEMBL17420565 | 0.72 | POLB (0.47) | TP53POLBELANESMN1; SMN2ALDH1A1 | |
| SCHEMBL17420469 | 0.71 | POLB (0.46) | TP53POLBELANEHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2723731-B1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS INC (US) | 2017-10-25 | — | — | EP | disclosed |
| US-8940735-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-8883797-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-20130012503-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2013-01-10 | — | — | US | disclosed |
| WO-2012177728-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2012-12-27 | — | — | WO | disclosed |
| WO-2012177725-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2012-12-27 | — | — | WO | disclosed |
| US-20120329802-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2012-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012503-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | TP53 2109/4885MAOB 246/4885POLB 1777/4885 |
| US-20120329802-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | TP53 2109/4885MAOB 246/4885POLB 1777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.